News | February 23, 2022
ACUITE upgrades ratings of Bal Pharma
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
The group had witnessed healthy revenue growth as revenue stood at Rs 251.14 crore in FY21.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Key takeaways of recent quarter & conference call highlights
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The stability is led by healthy demand in the domestic and emerging markets
Subscribe To Our Newsletter & Stay Updated
